HRP20110437A2 - Derivati rifamicina - Google Patents

Derivati rifamicina Download PDF

Info

Publication number
HRP20110437A2
HRP20110437A2 HR20110437A HRP20110437A HRP20110437A2 HR P20110437 A2 HRP20110437 A2 HR P20110437A2 HR 20110437 A HR20110437 A HR 20110437A HR P20110437 A HRP20110437 A HR P20110437A HR P20110437 A2 HRP20110437 A2 HR P20110437A2
Authority
HR
Croatia
Prior art keywords
formula
compound
alkyl
compounds
hydrogen
Prior art date
Application number
HR20110437A
Other languages
English (en)
Croatian (hr)
Inventor
Claudio Viscomi Giuseppe
Campana Manuela
Folegatti Mahena
Cannata Vincenzo
Righi Paolo
Rosini Goffredo
Original Assignee
Alfa Wassermann S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann S.P.A. filed Critical Alfa Wassermann S.P.A.
Publication of HRP20110437A2 publication Critical patent/HRP20110437A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
HR20110437A 2009-04-20 2010-03-18 Derivati rifamicina HRP20110437A2 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2009A000653A IT1397617B1 (it) 2009-04-20 2009-04-20 Nuovi derivati della rifamicina
PCT/IB2010/051183 WO2010122436A1 (fr) 2009-04-20 2010-03-18 Dérivés de rifamycine

Publications (1)

Publication Number Publication Date
HRP20110437A2 true HRP20110437A2 (hr) 2011-09-30

Family

ID=41228810

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110437A HRP20110437A2 (hr) 2009-04-20 2010-03-18 Derivati rifamicina

Country Status (27)

Country Link
US (2) US8318763B2 (fr)
EP (1) EP2421869B1 (fr)
JP (1) JP5661100B2 (fr)
KR (1) KR101555860B1 (fr)
CN (1) CN102405223A (fr)
AR (1) AR076340A1 (fr)
AU (1) AU2010240638B2 (fr)
BR (1) BRPI1005979A8 (fr)
CA (1) CA2743801C (fr)
CL (1) CL2011002597A1 (fr)
CO (1) CO6362013A2 (fr)
DK (1) DK2421869T3 (fr)
EA (1) EA020201B1 (fr)
ES (1) ES2535327T3 (fr)
HR (1) HRP20110437A2 (fr)
IL (1) IL212942A (fr)
IT (1) IT1397617B1 (fr)
MA (1) MA33320B1 (fr)
MX (1) MX338334B (fr)
NZ (1) NZ595884A (fr)
PL (1) PL2421869T3 (fr)
PT (1) PT2421869E (fr)
SG (1) SG171989A1 (fr)
TN (1) TN2011000265A1 (fr)
TW (1) TWI422372B (fr)
UA (1) UA105775C2 (fr)
WO (1) WO2010122436A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
MX2015003108A (es) * 2012-09-12 2015-09-10 Salix Pharmaceuticals Inc Metodos de administracion de rifaximina sin producir resistencia a los antibioticos.
CN103709177B (zh) * 2013-12-20 2016-02-24 武汉工程大学 利福霉素类沃尼妙林杂合抗生素及其制备方法
NZ723571A (en) * 2014-05-12 2020-02-28 Alfasigma Spa New solvated crystal form of rifaximin, production, compositions and uses thereof
MX386622B (es) * 2017-06-26 2025-03-19 Biofer Spa Derivados de pirido-imidazo rifamicina como agente antibacteriano

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2043847A1 (fr) * 1969-05-30 1971-02-19 Takeda Chemical Industries Ltd
SU465795A3 (ru) * 1972-05-05 1975-03-30 Группо Лепетит (Фирма) Способ получени рифамицина в.
CH571064A5 (en) * 1973-03-01 1975-12-31 Archifar Ind Chim Trentino Recovery of rieamycin from broths - by oxidn to an insol form
US3847903A (en) * 1973-03-01 1974-11-12 Archifar Ind Chim Trentino Method for extracting and isolating rifamycin o from fermentation broths of rifamycins
US4267274A (en) * 1973-04-26 1981-05-12 Gruppo Lepetit S.P.A. Streptomyces mediterranei mutant capable of production of rifamycin B
GB1470426A (en) 1974-08-30 1977-04-14 Lepetit Spa Rifamycins
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin

Also Published As

Publication number Publication date
IT1397617B1 (it) 2013-01-18
ES2535327T3 (es) 2015-05-08
PT2421869E (pt) 2015-04-29
IL212942A0 (en) 2011-07-31
US8318763B2 (en) 2012-11-27
TWI422372B (zh) 2014-01-11
CA2743801A1 (fr) 2010-10-28
EP2421869B1 (fr) 2015-03-11
JP2012524060A (ja) 2012-10-11
CA2743801C (fr) 2017-03-07
DK2421869T3 (da) 2015-06-08
MX2011011026A (es) 2011-11-02
HK1163663A1 (en) 2012-09-14
BRPI1005979A8 (pt) 2017-12-26
CN102405223A (zh) 2012-04-04
AR076340A1 (es) 2011-06-01
AU2010240638A1 (en) 2010-10-28
EA201190216A1 (ru) 2012-02-28
TN2011000265A1 (en) 2012-12-17
JP5661100B2 (ja) 2015-01-28
CL2011002597A1 (es) 2012-03-23
SG171989A1 (en) 2011-07-28
CO6362013A2 (es) 2012-01-20
PL2421869T3 (pl) 2015-08-31
AU2010240638B2 (en) 2014-06-05
US20100267654A1 (en) 2010-10-21
WO2010122436A1 (fr) 2010-10-28
US8765778B2 (en) 2014-07-01
IL212942A (en) 2015-06-30
EA020201B1 (ru) 2014-09-30
ITMI20090653A1 (it) 2010-10-21
TW201039819A (en) 2010-11-16
MA33320B1 (fr) 2012-06-01
EP2421869A1 (fr) 2012-02-29
KR101555860B1 (ko) 2015-09-25
US20130287692A1 (en) 2013-10-31
BRPI1005979A2 (pt) 2016-02-10
NZ595884A (en) 2012-12-21
UA105775C2 (uk) 2014-06-25
KR20120014110A (ko) 2012-02-16
MX338334B (es) 2016-04-11

Similar Documents

Publication Publication Date Title
HRP20110437A2 (hr) Derivati rifamicina
EP2536734B1 (fr) Formes de rifaximine, et leurs utilisations
US8404704B2 (en) Use of polymorphic forms of rifaximin for medical preparations
US5728710A (en) Rapamycin derivatives
AU2012214239B2 (en) Forms of Rifaximin and uses thereof
CN104327097B (zh) 雷帕霉素的三氮唑衍生物和用途
EP0333176A2 (fr) Dérivé de la benzoxazinorifamycine substitué, procédé de préparation et agent antibactérien le contenant
CN113773316B (zh) 一种tnik抑制剂及其制备方法和用途
CN111116707B (zh) 一种Rakicidins氨基甲酸酯类衍生物及其制备方法与应用
EP0787494B1 (fr) Utilisation des derivates de rifamycine pour la manufacture d'un medicament contre les maladies causées par une infection par helicobacter pylori
WO2014049356A1 (fr) Dérivés de kétolides d'érythromycine portant des modifications en c-10
JPH08506117A (ja) ラパマイシン誘導体、その製造法および用途
CN102838661A (zh) 万古霉素或去甲万古霉素类似物及其药用用途
US11597743B2 (en) Glycosyltransferase inhibitors for treatment of solid tumors
IT201900012888A1 (it) Inibitori della antibiotico-resistenza mediata da ArnT
HK1191558B (en) Forms of rifaximin and uses thereof
HK1191558A (en) Forms of rifaximin and uses thereof
HK1179608B (en) Forms of rifaximin and uses thereof

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20140228

Year of fee payment: 5

OBST Application withdrawn